Find drug development pipeline and deal Updates information

Lead Product(s): Idursulfase beta

Therapeutic Area: Genetic Disease

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: General Atlantic

Deal Size: $98.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing February 18, 2020

Details:

The proceeds, will be used to accelerate and expand the CANbridge rare disease pipeline through internal development and external partnerships, further build CANbridge’s commercial infrastructure.